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Abstract: The physiopathology of fatty liver and metabolic syndrome are influenced by diet, life style
and inflammation, which have a major impact on the severity of the clinicopathologic outcome of
non-alcoholic fatty liver disease. A short comprehensive review is provided on current knowledge of
the pathophysiological interplay among major circulating effectors/mediators of fatty liver, such as
circulating lipids, mediators released by adipose, muscle and liver tissues and pancreatic and gut
hormones in relation to diet, exercise and inflammation.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is associated with a wide pathological spectrum, ranging
from indolent liver fat storage, associated with an asymptomatic benign clinical course, to progressive
cardiovascular, metabolic and/or liver and kidney diseases with higher cancer risks. Insulin resistance
(IR) plays a pivotal role in the pathogenic switch of fatty liver. IR as a hallmark of metabolic
syndrome stems from the complex dimensional interplay among inflammation and key circulating
mediators, organs and tissues, genetic background and major conditioning factors, such as lifestyle
(i.e., diet and physical activity). Here, we review the current knowledge on the dynamics of
major circulating effectors/mediators of fatty liver, such as circulating lipids, released compounds
from adipose, muscle and liver tissues and pancreatic and gut hormones in relation to lifestyle
(i.e., diet and exercise) and inflammation. As renal function is frequently altered in patients with
NAFLD, contributing to organ damage progression, the interplay with renal pathophysiology has also
been addressed for circulating effectors/mediators other than pancreatic hormones.
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2. Circulating Lipids
2.1. Free Fatty Acids (FFA)
Circulating FFA, which represent the major source of hepatic fat accumulation in patients with
NAFLD, are mainly derived from adipose tissue lipolysis and partly from lipoprotein spill over and
are the major fuel substrate for all tissues, except brain during fasting. Thus, their plasma levels are
high during fasting and decline after feeding because of the anti-lipolytic action of insulin. In the
presence of adipose tissue insulin resistance, FFA levels are high, despite high levels of circulating
insulin, because of the resistance to the anti-lipolytic action of this hormone [1,2]. FFAs are involved in
the pathogenesis of different metabolic disorders associated with insulin resistance, and different forms
of FFA have different implications in cardio-metabolic disorders, ranging from protective to harmful
effects [3–7]. Plasma FFAs are reabsorbed in various organs where, if not oxidized, they accumulate
under the form of triglycerides within intra-cytoplasmic lipid droplets, and some lipid intermediates,
such as or diacyl-glycerols (DAG), promote cell lipotoxicity and mitochondrial dysfunction (Figure 1).
Hepatic FFAs can be exported as very low density lipoproteins (VLDL), which can contribute to high
circulating triglycerides and low density lipoproteins (LDL), reduced high density lipoproteins (HDL)
and an increased risk of atherosclerosis [8].
2.1.1. FFA and Diet
Consistent with the above evidence is that a higher saturated fatty acid (SFA) intake was
associated with increased cardiovascular risk [9], whereas a higher intake of polyunsaturated fatty
acids (PUFA) showed a protective effect [10], even if contradictory data arose from studies assessing
the impact of PUFA supplementation on cardiovascular outcomes [11]. From a practical point of view,
a recommended diet should be rich in PUFA and low in SFA.
2.1.2. FFA and Exercise
FFA mobilization and oxidation are higher during low and prolonged versus short and high
intensity exercise [12]. In fact, during high intensity exercise, most energy is derived from glucose,
while the highest use of FFA as a substrate occurs during low intensity exercise (25% of VO2 max).
2.1.3. FFA and Inflammation
Elevated plasma FFA levels, affected also by diet and exercise and resulting from obesity or
high-fat feeding, can cause insulin resistance, as well as low-grade inflammation [13]. Recently,
the activation of the c-Jun terminal kinase (JNK) pathway by SFA was demonstrated in in vivo
investigations [14], contributing to the development of hepatic steatosis and insulin resistance, as well
as activation of pro-inflammatory M1 macrophages. Other in vitro studies showed that palmitate
may induce endoplasmatic reticulum (ER) and oxidative stress in hepatocytes [15] and trigger the
inflammasome via the activation of macrophages through TLR2/1 dimerization [16]. On the contrary,
the contribution of unsaturated fatty acids (e.g., oleate, linoleate) to insulin resistance is still debated;
they seem unable to affect the cell, but can impact TG storage [17]. Finally, FFAs are the source of
diacyl glycerol (DAG), triglycerides and other metabolites, such as ceramides, which are synthesized
in the ER of hepatocytes from long-chain SFA, as a substrate [18]. Ceramides were shown to be
lipotoxic to pancreatic cells and involved in hepatic insulin resistance [19], but direct evidence of
their pro-apoptotic role on hepatocytes is missing [20]. Increased hepatic ceramides and saturated TG
and FFA were found in patients with NAFLD [21]. ER stress contributes to NASH progression, and
saturated FFAs were shown to induce an ER stress response in hepatocytes and increased levels of ER
stress in patients with NAFLD/NASH [22].
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2.1.4. FFA and Nonalcoholic Fatty Liver Disease (NAFLD)
The above-mentioned effect of FFA on insulin resistance and low grade inflammation can explain
the link between FFA and NAFLD/NASH. Recent in vitro and in vivo studies support the hypothesis
that FFAs, which are not esterified and compartmentalized in lipid droplets, may induce irreversible cell
damage and trigger pro-inflammatory signaling pathways (lipotoxicity), either alone or in combination
with other lipid metabolites [23–25]. In addition, other in vitro and in vivo studies have shown that
inhibiting hepatic TG synthesis results in an amelioration of hepatic steatosis, but exacerbates liver cell
damage due to an increased intra-hepatic accumulation of FFAs [26]. All together, these observations
suggest a possible protective role for increased hepatic TG synthesis against FFA-mediated cell toxicity.
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increasing hepatic glucose production and hepatic insulin resistance. Several hormones secreted by 
the gastrointestinal tract regulate glucose/lipid metabolism, as well as food intake and, thus, might be 
implicated in the development of NAFLD. Impaired GLP-1 secretion and decreased levels of GLP-1 
receptors have been reported in the liver of subjects with NAFLD, which further impair hepatic 
glucose and lipid metabolism. Ghrelin modulates appetite and insulin secretion, and an increased 
Figure 1. The key metabolic players and the major pathogenic pathways involved in NAFLD.
Fatty liver is considered to be the hepatic component of metabolic syndrome. Systemic insulin
resistance reduces adiponectin and increases leptin concentrations, while adipose tissue lipolysis
is not suppressed (as shown with the “//” symbol), despite high circulating insulin levels, and plasma
FFA concentration is increased. Increased glucagon levels have also been reported in NAFLD patients.
The altered insulin/glucagon ratio promotes DNL, glycogenolysis and gluconeogenesis in the liver,
thus increasing hepatic glucose production and hepatic insulin resistance. Several hormones secreted
by the gastrointestinal tract regulate glucose/lipid metabolism, as well as food intake and, thus,
might be implicated in the development of NAFLD. Impaired GLP-1 secretion and decreased levels
of GLP-1 receptors have been reported in the liver of subjects with NAFLD, which further impair
hepatic glucose and lipid metabolism. Ghrelin modulates appetite and insulin secretion, and an
increased acylated/deacylated ghrelin ratio exerts anti-inflammatory properties.The liver secretes
several hepatokines, including SeP, which further enhance insulin resistance, increase the production
of small LDL particles that induce atherosclerosis and promote oxidative stress. Adipose tissues
secrete adipokine-like leptin and adiponectin that are involved in the modulation of inflammation,
fatty acid oxidation and energy expenditure, insulin resistance and insulin secretion. Myokines can
also affect glucose and lipid metabolism, e.g., irisin, of which secretion is stimulated by exercise
and induces thermogenesis, although its role has not yet been completely elucidated. Small red
arrows versus the top: indicate increased concentrations; small red arrows versus the bottom: indicate
reduced concentrations.
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2.1.5. FFA and Kidney
The same mechanisms advocating FFA in the pathogenesis of NAFLD/NASH could also
be involved in chronic kidney disease (CKD), where the lipotoxicity of FFAs in kidney cells,
and in particular on podocytes [27], via ER stress, could explain the pathogenic role of obesity in
CKD. Additionally in CKD, although polyunsaturated FAs (such as linoleic acid) probably play a
protective role on the kidneys, saturated FFAs, such as palmitic acid, are responsible for intracellular
lipotoxicity [28,29].
2.2. Cholesterol
Cholesterol is a major lipotoxic molecule, critical in the development of experimental and human
metabolic disorders, such as atherosclerosis [30,31]. Different lines of evidence have reported that the
accumulation of LDL in vessels make macrophages and smooth muscle cells able to convert esterified
cholesterol into cholesterol [31–33]. When intra- and extra-cellular accumulation of cholesterol cannot
be removed HDL mediated mechanisms, this leads to the generation of cholesterol crystals that, in turn,
promote cell death, intima injury and atherosclerotic plaque destabilization [31]. The Seven Countries
Study clearly reported a strong link between circulating total cholesterol levels, cardiovascular
mortality and diet, with a higher intake of both refined sugar and fat being associated with poor
outcomes [31], while dietary fibers have a protective effect [33,34].
2.2.1. Cholesterol and Diet
The influence of cholesterol-free diets on cholesterol serum levels is controversial, in spite of the
very large number of different cholesterol-free diet programs [35]. One major reason for this may
be the fact that the impact of different diet components on plasma lipid composition is mediated
by gut microbiota [36]. The interactions between gut microbiota and dietary lipids in regulating
liver and plasma lipid composition, liver gene expression and hepatic cholesterol metabolism were
recently shown in germ-free and normally-raised mice [36]. In a study on mice fed lard, gut microbiota
increased hepatic, but not serum, levels of cholesterol and cholesteryl esters, while, in mice fed fish oil,
neither hepatic nor serum levels of cholesterol and cholesteryl esters were affected [36].
2.2.2. Cholesterol and Exercise
Considering the effect of exercise on cholesterol levels [37], available evidence suggests the
particular effectiveness of higher-intensity aerobic exercise [38] and moderate-intensity resistance
training [39], with a dose-response relationship between activity levels and increases in HDL
cholesterol. However, in order to observe a reduction in plasma cholesterol with exercise training,
a reduction in caloric intake and dietary fat during the exercise training program, resulting in a decrease
in body weight/body fat, is important [40].
2.2.3. Cholesterol and Inflammation
Cholesterol accumulation in macrophages leads to the induction and secretion of two
major inflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6),
which induce inflammation via NLRP3 (nucleotide-binding domain, leucine-rich-containing family,
pyrin domain-containing-3) activation and the production of IL1-β and C-reactive protein, suggesting
that excess ER cholesterol triggers endogenous cellular events. This proinflammatory activity can
explain the link between high cholesterol levels, cholesterol deposition in atherosclerotic plaques and
vascular damage [41].
2.2.4. Cholesterol and NAFLD
Lipidomic analyses of NAFLD have demonstrated that, apart from triglycerides, there is also
an accumulation of free cholesterol (FC) without a similar increase in cholesterol esters (CE) in both
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NAFLD and NASH [42] (Figure 1). Again, the above-mentioned cholesterol-related proinflammatory
mechanisms, involved in vascular damage, have been also linked to cholesterol-mediated liver damage
in NASH [31–33]. Along this line, multiple and complex alterations occur in the pathways of cholesterol
homeostasis in both NAFLD and NASH [43]. Consistently, statin use has been associated with possible
protection from hepatic damage and fibrosis in NAFLD [44].
2.2.5. Cholesterol and Kidney
Several findings suggest the role of systemic and renal lipids in kidney disease development
and progression [45]. In fact, lipid loaded cells (i.e., foam cells) are frequently observed in many
progressive nephropathies, such as in experimental diabetic kidney disease (DKD) and in focal
segmental glomerular sclerosis (FSGS) or minimal change nephropathy in humans [46–48]. Secondly,
the high prevalence, in African American subjects, of genetic variants of the APOL1 gene, encoding
apolipoprotein L1 (a component of HDL), may explain the high susceptibility to nephropathy, in
particular to FSGS, of this ethnic group [49]. Finally, some interventions that interfere with lipid
accumulation in glomerular cells (podocytes) are effective in reducing kidney damage in some
experimental kidney diseases [50]. Although no clear benefit of statin use on chronic kidney disease
(CKD) occurrence and/or progression has been demonstrated in a clinical setting [51], the mechanism(s)
by which cholesterol might play a causal role in CKD may be more complex than that which is only
related to serum cholesterol concentration; again, involving its ability to activate pro-inflammatory
mechanisms already involved in atherosclerosis and NASH [45].
3. Adipose Tissue Released Compounds
3.1. Adiponectin
Adiponectin is a cytokine that is mostly produced by adipocytes, its expression being primarily
determined by adipocyte size and insulin sensitivity, with larger, insulin-resistant adipocytes being
less productive [52,53]. It is a “protective” adipocytokine, involved in the regulation of glucose and
lipid metabolism, as well as in inflammation inhibiting NF-κB and TNF-α production in macrophages;
consistent with these data, its serum concentrations are inversely related to obesity and diabetes [54].
Adiponectin levels are inversely related to insulin resistance and are lower in obese subjects and
patients with established insulin resistance, e.g., in type 2 diabetes, NAFLD/NASH and hypertension.
3.1.1. Adiponectin and Diet
High-fat, but not low fat, diets were associated with increased adiponectin levels, whereas a
modest increase was reported with n-3 polyunsaturated fatty acids (PUFA) supplementation [55];
however, on the contrary, conjugated linoleic acid supplementation showed a reduction in adiponectin
levels [55]. In mice, a high-carbohydrate diet was shown to increase adiponectin levels [56], and in
humans, Rezvani et al. reported a significant increase of adiponectin levels during the consumption of
glucose, but not fructose [57]. Some evidence suggests that adiponectin production by adipocytes is
regulated via insulin-stimulated glucose utilization [58].
3.1.2. Adiponectin and Exercise
Mild or moderate physical activity does not change adiponectin levels, though a positive effect
was reported with longer exercise [59]. Consistently, increased serum adiponectin levels paralleled
the improvement of carotid vascular function in obese individuals undergoing intense exercise and
moderate caloric restriction [60].
3.1.3. Adiponectin and Inflammation
While the impact of diet and exercise on adiponectin is controversial, the anti-inflammatory
activity of this adipokine, able to inhibit NF-κB and TNF-α production in macrophages, is well
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established (Figure 1); consistent with these data, its serum concentrations are inversely related
to obesity and chronic metabolic disorders, such as insulin resistance and diabetes. In contrast,
adiponectin levels are elevated in classic chronic inflammatory/autoimmune diseases unrelated
to increased adipose tissue, such as rheumatoid arthritis, systemic lupus erythematosus (SEL),
inflammatory bowel disease, type 1 diabetes (T1D) and cystic fibrosis [61].
3.1.4. Adiponectin and NAFLD
Due to the above-mentioned insulin sensitizing and anti-inflammatory activity of adiponectin,
its plasma levels are decreased in patients with NAFLD and are associated with fat content [62].
After treatment with thiazolidinediones, adiponectin values increase in NASH as a sign of improvement
of hepatic steatosis, necroinflammation and, most importantly, fibrosis [63].
3.1.5. Adiponectin and Kidney
Adiponectin, due to its insulin sensitizing and anti-inflammatory activities, has a protective role
on the kidney [64]. In fact, low adiponectin levels were associated with increased albumin urinary
excretion and histological evidence of kidney damage, both in experimental and clinical studies [65–67].
At odds with these findings, in CKD, the levels of adiponectin are often increased. Whether this finding
represents a compensatory phenomenon or just the consequence of the reduced renal clearance of a
relatively small molecule (30 kD) and/or of an altered signaling at cellular levels is still a matter of
debate [68–70].
3.2. Leptin
Leptin is a cytokine that is primarily secreted from adipose tissue, with a critical role in the
regulation of body weight and fat mass. In obese mice, leptin causes weight loss, increasing energy
expenditure and fatty acid oxidation, reducing appetite and triglyceride synthesis and counteracting
the lipogenic action of insulin [71]. Its role in humans is less clear-cut; only patients with lipodystrophy
have a beneficial effect when treated with leptin, while obese subjects do not lose weight. Circulating
leptin is strongly associated with both subcutaneous and visceral fat [72], and different studies have
hypothesized that obesity might induce a state of leptin resistance. High leptin levels are associated
with reduced insulin secretion, increased gluconeogenesis and reduced glucose uptake, leading to
hyperglycemia and ultimately contributing to increased insulin resistance [73–75] (Figure 1). Leptin
may negatively affect the cardiovascular system by exerting potential atherogenic, thrombotic and
angiogenic activities, as well as, even if with contrasting data, leading to cardiac hypertrophy [76].
3.2.1. Leptin and Diet
A higher energy storage is directly related to serum leptin levels [71]. Considering different types
of fatty acids: SFAs are associated with increased leptin levels, whereas MUFA and PUFA have an
opposite effect [71]. Finally, fiber and higher protein intake increase leptin sensitivity, which induces
central satiety [71].
3.2.2. Leptin and Exercise
Available evidence suggests that, while acute and short-term physical activity do not affect leptin
levels, longer exercise (at least 60 min) is associated with increased energy expenditure that could lead
to leptin decrease [59]. Accordingly, the adiponectin/leptin ratio results as an independent predictor
of carotid intima-media thickness (CIMT) alterations [77].
3.2.3. Leptin and Inflammation
Leptin may exert pro-inflammatory activity by the impairment of NO-related vassal relaxation,
via increased oxidative stress, and by increased endothelin expression [54,78], by potentiating the
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effect of angiotensin II, which, in turn, increases leptin synthesis by inducing pro-inflammatory
cytokines (e.g., TNF-α, IL-6 and MCP-1 receptor) by increasing the expression of adhesion molecules
(e.g., VCAM-1, ICAM-1 and E-selectin). These features could explain why hyperleptinemia is observed
in many chronic inflammatory diseases [79,80], such as atherosclerosis, and how it can participate
in damage.
3.2.4. Leptin and NAFLD
A recent meta-analysis indicates that circulating leptin levels are higher in patients with NAFLD
than in controls, and higher serum leptin levels were associated with an increased severity of
NAFLD [81]. This is in agreement with the above-mentioned evidence of inflammatory-mediated
damage related to leptin and potential involvement in NASH pathogenesis.
3.2.5. Leptin and Kidney
Leptin is cleared from circulation by glomerular filtration and metabolic degradation in renal
tubules, which accounts for the elevated levels of leptin in CKD patients [79]. Given its anoxygenic and
pro-inflammatory activities, leptin might contribute to malnutrition and inflammation, often observed
in CKD patients, and a consistently higher risk of cardio-vascular morbidity and mortality [80,82,83].
Again, common inflammatory pathways could account for the role of leptin in kidney damage.
4. Pancreatic Hormones and NAFLD
4.1. Insulin
Insulin is secreted by the pancreas in response to changes in glucose concentrations that occur
after a meal or after hormone release, such as catecholamines or glucagon [2]. Insulin tightly regulates
glucose metabolism and plasma concentrations, on the one hand, by promoting glucose uptake in
skeletal muscle and liver (for glucose oxidation or glycogen storage), in adipose tissue (where glucose
is utilized for triglyceride synthesis) and, on the other hand, by suppressing hepatic glucose production.
Insulin also acts on lipid metabolism, as it promotes fatty acid re-esterification into triglycerides in
adipose tissue and liver, but also inhibits peripheral adipose tissue lipolysis (Figure 1). Thus, the role
of insulin in the development of NAFLD is crucial. In the presence of insulin resistance, the pancreas
is stimulated to increase insulin secretion to overcome the defect in peripheral glucose uptake and to
decrease hepatic glucose production. Since the pancreas releases secreted insulin into the portal vein
and the liver clears most of it, the amount of insulin that reaches the liver is much higher than in the
periphery. Thus, when hepatic glucose production rates are high in the presence of high insulin values,
it is recognized as a sign of hepatic insulin resistance [84]. Insulin mainly acts in suppressing hepatic
glycogenolysis, rather than gluconeogenesis; however, until “hepatic autoregulation” is maintained,
fasting glucose concentrations remain within normal ranges (Figure 1). When hepatic autoregulation
is lost, both components of hepatic glucose production (i.e., glycogenolysis and gluconeogenesis) are
increased and assist in the development of fasting hyperglycemia and type 2 diabetes [85]. Finally,
different evidence supports a bidirectional link between insulin resistance and chronic inflammation.
However, this topic is not the main goal of the present paper, while being the object of a huge debate
in the literature, as reported in different reviews [86–88].
4.1.1. Insulin and Diet
A carbohydrate-rich diet (with a high glycemic index) determines higher glucose excursion and
triggers a higher insulin secretion rate. Moreover, both lipids and amino acids determine increased
insulin secretion; oral amino acids elicit a stronger and sustained insulin secretion, as compared to
amino acids given intravenously [89]. In addition, lipids have an incretin effect, and a diet high
in saturated fats determines insulin resistance and a higher glucose-stimulated insulin secretion
(GSIS) [90]. A sustained increase in plasma free fatty acids by long-term intralipid infusion increases
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GSIS, but this response was found to be impaired in non-diabetic subjects, genetically predisposed to
develop type 2 diabetes [91].
4.1.2. Insulin and NAFLD
Insulin promotes de novo lipogenesis (DNL) and glyceroneogenesis [25] (Figure 1). Both pathways
are increased in NAFLD, even in non-diabetic patients, contributing to the synthesis of hepatic
triglycerides and the promotion of hepatic steatosis [92]. In addition, patients with NAFLD have
increased hepatic synthesis of palmitate through DNL, and this increases the risk of lipotoxicity and
cell damage [25,93]. Finally, insulin, in the context of insulin resistance, prompts fibrogenesis by stellate
cells [94,95]. Most patients with NAFLD have normal fasting glucose concentrations, but high levels of
fasting insulin and high hepatic insulin resistance. Thus, it is not surprising that NAFLD is a major
risk factor for the development of type 2 diabetes.
4.1.3. Insulin and Exercise
Exercise increases the demand of glucose in the periphery (muscle), and thus, there is a demand
for increased endogenous glucose production (EGP). However, since glucose is immediately used by
the muscle to produce ATP, glucose concentrations are usually stable, and thus, there is no stimulus
for an increase in insulin secretion. However, other hormones, such as glucagon and catecholamine,
are increased during exercise and stimulate EGP [12,96].
4.2. Glucagon
Glucagon is produced and secreted from alpha cells located in clusters of endocrine cells, in
the islets of Langerhans, distributed throughout the pancreas [97]. Glucagon secretion is found to
be increased, not only in diabetes, but also in several insulin resistant states, including NAFLD [98].
The role of glucagon is opposite that of insulin (Figure 1); glucagon stimulates glucose production
via activation of hepatic glycogenolysis and gluconeogenesis by inhibition of glycolysis [98]. It also
regulates fatty acid metabolism via stimulation of peripheral lipolysis, reduction of malonyl-CoA and
stimulation of fatty acid oxidation [99]. However, the most recent data indicate that glucagon is also
involved in amino acid metabolism, both because amino acids can stimulate glucagon secretion and
because glucagon can stimulate protein metabolism [98].
4.2.1. Glucagon and Diet
Glucose is the most important regulator of pancreatic glucagon secretion. In normal glucose
tolerant (NGT) subjects, when glucose concentrations are high, glucagon secretion is suppressed, and
when there are low glucose concentrations, glucagon secretion is increased, securing an essential
supply of energy (i.e., glucose) to the central nervous system and muscles. In patients with diabetes,
glucagon concentrations are elevated in the fasting state and fail to decrease appropriately, or even
increase, during an oral glucose tolerance test (OGTT) or after ingestion of a mixed meal [100–102].
Certain amino acids, such as glutamine, alanine and arginine, are also important glucagon secretors,
with the latter being the most potent stimulatory amino acid [103,104]. Fat intake also increases
glucagon secretion [105].
4.2.2. Glucagon and NAFLD
Since glucagon stimulates lipolysis and reduces lipogenesis [99], glucagon was proposed as a
therapy option for hepatic steatosis [106]. Similarly, it was thought that the reduction of glucagon
signaling, i.e., via the use of glucagon receptor antagonists, might lead to the accumulation of lipids
in the liver [107]. However, more recent studies [108] have shown that glucagon receptor knockout
mice have reduced hepatic lipid contents compared with wild-type mice. The impact of glucagon on
NAFLD has not been elucidated. Junker and colleagues [109] have shown that patients with NAFLD
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have fasting hyperglucagonemia, independent of their glucose tolerance status. According to the
authors, this finding suggests that NAFLD might be involved in the generation of hyperglucagonemia
in T2D, which is supported by several animal studies [110].
4.2.3. Glucagon and Exercise
Exercise induces an increase in glucagon secretion in order to increase hepatic glucose production
and gluconeogenesis. However, although pancreatic hormones are important in the stimulation of
EGP during low or moderate intensity exercise, during strenuous exercise (i.e., 80% VO2 max), EGP is
increased, mainly because of increased catecholamine, while changes in glucagon and insulin are not
necessary to stimulate the increase in Ra [96].
4.2.4. Glucagon and Inflammation
Patients with trauma, burns or sepsis normally exhibit increased plasma levels of glucagon,
in order to promote gluconeogenesis, increase circulating glucose and compensate for the energetic
demand of the body during these extreme situations [111]. Interestingly, significant increases of both
glucagon and inflammatory mediators occur after a high fat high carbohydrate meal, as compared
with an American Heart Association-recommended meal [112]. Plasma IL-6, a pro-inflammatory
cytokine, is elevated in physiological and pathophysiological settings where glucagon is also elevated,
such as exercise [113], diabetes [114] and inflammatory stress [115]. Tweedell et al. have demonstrated
that IL-6-deficient (IL-6-KO) mice have a blunted glucagon response to acute inflammation compared
with their wild-type littermates, while glucagon response is completely rescued by intravenous
replacement of IL-6 [116]. Consistent with this, Ortega and colleagues demonstrated that, in patients
with altered glucose tolerance, but not in NGT subjects, circulating glucagon levels were associated
with inflammatory mediators, such as IL-6 [111].
5. Gut Released Hormones
5.1. GLP-1
Glucagon-like peptide 1 (GLP-1) is an incretin hormone produced mainly by the L-cells of the gut
in response to food intake. GLP-1 has an important role in the regulation of glucose metabolism, since
it potentiates insulin secretion and inhibits glucagon release [117,118] (Figure 1). GLP-1 exerts its effect
through binding to GLP-1 receptors, which are mainly expressed in the pancreas and brain, but also
in the heart, liver, colon and kidney [117]. Other effects of GLP-1 include the central suppression of
appetite and the induction of satiety by delaying gastric emptying [117,119]. Other than these classical
activities, GLP-1 seems to be able to modulate the function of different key organs by interacting with
GLP-1 receptors present in the lung, stomach, liver, colon, kidney and heart. Consistent with these data,
growing evidence suggests a direct protective effect of GLP-1 on the cardiovascular system [117,119].
5.1.1. GLP-1 and Diet
GLP-1 release can be stimulated by mixed meals or individual nutrients, including glucose and
other sugars, fatty acids, essential amino acids and dietary fiber. Oral, but not intravenous, glucose
administration stimulates GLP-1 secretion in humans [120].
5.1.2. GLP-1 and Exercise
Exercise-related studies have shown that healthy people have increased levels of incretin
hormones, such as GLP-1, after physical activity [121]. Lee et al. showed higher GLP-1 levels after
high intensity vs. low intensity exercise, with matched energy expenditures [122].
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5.1.3. GLP-1 and Inflammation
GLP-1 receptor agonists (GLP-1RAS) have anti-inflammatory effects in different cell types,
including human umbilical vein endothelial cells, glomerular endothelial cells, monocytes and
macrophages [123,124]. GLP-1 levels decreased for a mean duration of 7.5 months in a retrospective
analysis of 110 obese patients with T2D who were treated with liraglutide [125]. Consistently, TNF-α
induced systemic inflammation and reduced GLP-1 concentrations, thereby reducing the suppression
of endogenous glucose production (EGP) during GLP-1 infusion [126].
5.1.4. GLP-1 and NAFLD
In vitro studies have shown that human hepatocytes express the GLP-1 receptor [127,128].
In liver tissue, the expression of GLP-1 receptors is controversial [117], but Svegliati-Baroni was
able to demonstrate that, in human livers of subjects with NASH, both the expression and protein
content of GLP-1R were decreased compared to subjects without NASH [128]. In subjects with hepatic
steatosis, open-label studies have shown that exenatide may improve liver enzymes and decrease
steatosis when assessed by magnetic resonance spectroscopy (MRS) [129,130] and even improve
histology [131]. A recent study by Armstrong et al. has shown that, after 48 months of double blind
treatment with liraglutide vs. placebo (the LEAN study), 39% of patients receiving liraglutide vs. 9% of
those receiving placebo had a resolution of definite non-alcoholic steatohepatitis with no worsening in
fibrosis [132]. Among the mechanisms that lead to the improvement in liver histology were significant
weight loss, reduced FFA flux to the liver, reduced de novo hepatic DNL and the above-mentioned
anti-inflammatory activities [133] (Figure 1). All in all, these findings qualify GLP-1RA as a potential
candidate for the treatment of NAFLD.
5.1.5. GLP-1 and Kidney
The effects of GLP-1 on glucose metabolism and inflammation, again, can indirectly benefit the
kidney. Furthermore, incretin may also have direct renal effects, since its specific receptors have
been described both in renal tubular and in glomerular cells [123,134]. One potential mechanism by
which GLP-1 may play a nephro-protective role is its natriuretic activity, due to the direct inhibition
of two key sodium transporters (Na-hydrogen exchanger-3 and sodium-glucose co-transporter-2) at
the tubular level [124]. Furthermore, GLP-1 might also have a positive hemodynamic effect on the
kidney by its stimulating and inhibitory effects on atrial natriuretic peptide (ANP) and angiotensin 2,
respectively [125].
5.2. Ghrelin
Ghrelin is a hormone that is mainly derived from the stomach and duodenum, with a key role
in growth hormone release and in food intake control by inducing appetite and controlling energy
expenditure [135]. Ghrelin molecules are present as two major endogenous forms, an acylated form,
which is the biologically-active form of ghrelin (AG), and a de-acylated form (DeAG) that does not bind
to ghrelin receptors [136]. AG is secreted before a meal and disappears more rapidly from plasma than
total ghrelin, with an elimination half-life of 9–13 vs. 27–31 min. The main organ that secretes ghrelin
is the stomach, where 65%–90% of the circulating ghrelin is synthesized, followed by the small bowel,
and in small amounts by other organs, including liver, pancreas, hypothalamus, kidney, liver, fat,
muscle and heart (Figure 1). Ghrelin O-acyltransferase (GOAT), the enzyme responsible for acylation,
was found to be involved in glucose metabolism, insulin resistance, lipid metabolism dysfunction
and inflammation [137,138]. GOAT is expressed in several organs, mainly in the gastrointestinal tract,
but also in the central nervous system, pancreas, heart, kidney, muscle, tongue, testis, thymus and
adipose tissue, but not in the liver.
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5.2.1. Ghrelin and Diet
Ghrelin levels (both AG and DeAG) increase with prolonged food deprivation and prior to meal
time, while decreases in weight gain, adiposity and in the post-prandial phase with a magnitude
proportional to caloric intake and macronutrient content [135,139,140]. GOAT expression and activity
and, thus, the availability of AG are modified by dietary lipids, in particular by the availability of short
and medium chain fatty acids [138]. Specifically, in a trial using isocaloric beverages, mostly containing
fat or carbohydrates or proteins, the lipid drink was the least effective, and the protein drink was the
most effective in lowering ghrelin levels, while the carbohydrate drink induced the largest drop in
ghrelin levels and was then followed by a significant rebound [141]. Van Name et al. studied the AG
response to glucose and fructose beverage in lean and obese adolescents (IS or IR). They found that
AG levels were suppressed after either glucose or fructose consumption in lean subjects. In obese IS
subjects, AG suppression was higher after glucose as compared to fructose consumption, whereas
in obese IR subjects, suppression of AG was blunted following fructose consumption [142]. Thus,
it would appear that, in addition to obesity in adolescents, the presence of insulin resistance further
limits the capacity of fructose to suppress this key orexigenic hormone and may continue to promote
hunger and overconsumption of fructose (or other calories), particularly in obese adolescents who are
insulin resistant.
5.2.2. Ghrelin and Exercise
Contradictory results exist on the effect of physical activity on ghrelin levels. Short-term
running, cycling or rowing exercise do not alter plasma total ghrelin [143–145]. On the other hand,
Mackelvie et al. showed that daily exercise for five consecutive days (1-h sessions of aerobic exercise)
is associated with an increase in plasma concentrations of AG, independent of the acute effect of
exercise and from changes in weight or markers of insulin sensitivity. In addition, the increase in AG
was more pronounced in normal weights compared with overweight subjects and was associated
with an increase in markers of appetite [146]. However, Shiiya et al. report that plasma AG, but not
DeAG levels, are suppressed during acute moderate exercise (cycle exercise for 60 minutes at 50% of
VO2 max) [146]. From a clinical point of view, this seems more reasonable since exercise increases
appetite and exercise is associated with an increase in ghrelin levels (total or acylated form). However,
more studies are needed to address the links between different forms of exercise, type, intensity and
duration and ghrelin yield.
5.2.3. Ghrelin and Inflammation
Ghrelin, and especially AG, exert anti-inflammatory activity by reducing the production
of pro-inflammatory cytokines, such as IL-1, IL-6 and TNF-α, via suppression of NF-κB [137].
The anti-inflammatory properties of ghrelin are consistent with the evidence from murine models that
ghrelin prevents diabetes [139] and has a protective cardiovascular effect. These anti-inflammatory
properties of ghrelin prompt the ghrelin-GOAT system as a promising new target for the treatment
of NASH [137]. AG can improve cardiac function by increasing cardiac output, ameliorating
cardiac contractility, acting on cardiac remodeling, reducing pulmonary hypertension, reducing fatal
arrhythmia after myocardial infarction and leading to vasodilation [139,147–150].
5.2.4. Ghrelin and NAFLD
Whether ghrelin levels are altered in NAFLD is still controversial, as Marchesini et al. [151]
reported low total ghrelin levels, while Mykhalchyshyn et al. [152] found high serum levels of AG
in NAFLD compared to controls. However, the above-mentioned effects of ghrelin on energy and
lipid metabolism, IR, inflammation and apoptotic cell death, which are common to both obesity and
NAFLD, highly suggest its interplay with NAFLD/NASH pathogenesis [137].
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5.2.5. Ghrelin and Kidney
In CKD, increased levels of total ghrelin, but not of AG, are frequently observed, due to the
reduced metabolic clearance of the total (mainly DeAG) by failed kidneys. The consequently-reduced
AG/DeAG ratio might contribute to inflammatory and malnutrition status, which is typical in many
CKD patients [153,154].
6. Muscle Released Compounds
6.1. Irisin
Irisin is a recently-discovered myokine, encoded by the FNDC5 gene; it is implicated in the
regulation of energy homeostasis and metabolism and the interactions between skeletal muscle
and other tissues (Figure 1). Irisin can induce the differentiation of white adipose into brown
adipocytes, along with upregulation of uncoupling protein 1 (UCP1) expression and an increase
in heat production [155,156]. Accordingly, circulating irisin can increase total energy expenditure,
thus reducing obesity and insulin resistance [155,156].
6.1.1. Irisin and Diet
Results of studies on the effect of diet on irisin concentrations are not unanimous. Some studies
report that irisin is not affected by food intake [157], while others indicate that irisin levels are positively
associated with increasing fruit intake and negatively associated with meat consumption [158]. Finally,
an inverse association between irisin and higher caloric intake has been shown [159].
6.1.2. Irisin and Exercise
The reported relationship between irisin and exercise are also contradictory. Some reports have
claimed increased irisin serum levels in subjects who exercise [156], while a recent meta-analysis
reported that chronic exercise training leads to significantly-decreased circulating irisin levels in
randomized controlled trials only, with evidence remaining inconclusive in some other studies [160].
6.1.3. Irisin, NAFLD and Inflammation
To the best of our knowledge, there is only one study in which lower irisin levels were
independently associated with higher intrahepatic triglyceride content, as assessed by 1H magnetic
resonance spectroscopy [161]. However, in a recent study by Polyzos and colleagues [162], irisin levels
were slightly higher in patients with NAFLD and significantly higher in NAFLD patients with portal
inflammation, as compared to those without portal inflammation. Contrasting data on higher or lower
serum irisin levels in relation with metabolic disorders, diet and exercise are worth further investigation
and could be mostly due to the inaccuracy and lack of standardization of commercially-available
ELISA assays. Mechanisms underlying the protective metabolic effects of irisin are not well understood
and seem to be mostly related to higher induced energy expenditure and not to anti-inflammatory
activities, such as NF-κB inactivation [157–159].
6.1.4. Irisin and Kidney
CKD patients have been reported to have lower, normal or higher energy expenditures than
normal healthy people. The discrepancy among the different studies may be due to many factors related
to the type of CKD stage, different therapies and also other, as of yet, unrecognized factors [163,164].
In this complex picture, a recent paper reported an inverse relationship between serum irisin levels
and intima-media thickness in dialysis patients [165]. It is also well known that malnourished CKD
patients have a worse outcome compared, not only with normally-nourished, but even obese CKD
patients. Irisin levels have been found to be lower in CKD patients, and its concentrations were directly
dependent on renal function and were related to the components of metabolic syndrome [166,167].
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Furthermore, higher irisin levels were associated with sarcopenia in peritoneal dialysis patients [165].
On the basis of these considerations, irisin has been suggested as a candidate for the malnutrition
status, often found in the more advanced stages of CKD. However, as for liver diseases, the role and
the mechanisms by which irisin affects CKD remain to be further investigated.
7. Liver-Released Compounds
7.1. Selenoprotein P
Selenoprotein P (SeP; encoded by SEPP1 in humans) is a secretory protein produced mainly by the
liver [168,169] that functions as a selenium transporter from the liver to the rest of the body [170,171].
SeP functions as a hepatokine that contributes to insulin resistance in type 2 diabetes [172] (Figure 1).
Importantly, the RNA interference-mediated knockdown of SeP improves insulin resistance and
hyperglycemia in a mouse model of type 2 diabetes, suggesting the suppression of SeP production in
the liver [173].
7.1.1. Selenoprotein P and Diet
SeP serum levels are directly correlated with the selenium (Se) diet supply (up to 0.1 mg/kg),
and Se plays a pivotal role in homeostasis, with its inextricable U-shaped link with health status.
Additional selenium intake may benefit people with low levels, whereas it may adversely affect those
with adequate-to-high selenium levels. Individuals with serum or plasma selenium concentration of
122 µg/L or higher should not be supplemented with selenium [174].
7.1.2. Selenoprotein P and Exercise
SeP serum levels represent the biologically-active body Se-pool that was shown to slowly decrease
during basic training in both trained and untrained individuals [175].
7.1.3. Selenoprotein P and Inflammation
SeP acts as an intracellular antioxidant in phagocytes, modulating inflammatory response via
switching macrophage differentiation from M1 to M2 and, of consequence, limiting pathogenicity
and oxidative damage [176,177]. On the other hand, SeP serum levels were shown to be lowered by
acute-phase inflammatory response [178,179]. A systemic inflammatory response produces cytokines,
inhibiting the expression of SEPP1 and reducing selenium levels; pro-inflammatory cytokines,
downregulating the SELP promoter in vitro, can, overall, reduce the anti-inflammatory effects of
SeP [180]. The interplay between SeP and inflammation may be the link of such a molecule with
atherosclerosis, and some controversial epidemiologic data in type 2 diabetes exist [181]. Higher serum
levels, inversely related to adiponectin and hepatic SeP concentrations, were reported in patients
with type 2 diabetes, with a direct and independent link between SeP and both serum C-reactive
protein levels and carotid intima-media thickness, while lower SeP expression was observed in
murine adipocytes [173,182,183]. Differences in diabetes-related inflammation and the U-shaped
association between SeP and type 2 diabetes risk, mimicking the U-shaped link of Se with health
status, might explain some of the apparently contradictory epidemiologic findings. All of these data
are worthy of further studies and validation, but indicate the key role of SeP in inflammatory-related
cardiovascular alterations.
7.1.4. Selenoprotein P and NAFLD
SeP was found to be increased in NAFLD patients after correction for confounding factors [184].
However, the role of SeP in NAFLD remains to be well elucidated, even if they are able to act,
as mentioned earlier, by their ability to modulate inflammatory response and insulin resistance.
In addition, different evidence suggests that metformin improves systemic insulin sensitivity through
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the regulation of SeP production, suggesting a novel potential therapeutic approach to treating type 2
diabetes [185].
7.1.5. Selenoprotein P and Kidney
SeP is the major carrier transporting selenium to target tissues and organs, including kidneys,
were it is taken up by mechanisms, which are dependent, by specific receptor-related proteins [186].
According to Reinhardt and colleagues, in patients with CKD, SeP concentrations increase with
impaired renal function (even after correction for age and CRP concentrations), whereas SeP
concentrations are significantly lower in dialysis patients [187]. The reasons for the discrepant SeP
concentrations among the stages of chronic renal failure are not yet completely defined, though the
increased inflammatory status in dialysis patients [188] could play an important pathogenic role.
7.2. Fetuin-A
Human Fetuin-A/a2-Heremans-Schmid glycoprotein is an abundant 59-kDa serum glycoprotein,
produced principally by the liver (thus, it can be classified as a “hepatokine”), and adipose tissue [189].
It works as a natural inhibitor of insulin receptors in the liver and skeletal muscle [190] and also
exerts pro-adipogenic effects and suppresses adiponectin release [191]. Deletion of Fetuin-A improves
insulin resistance and dyslipidemia and enhances glucose clearance in mice [192], whereas with
genetic variants in humans, Fetuin-A has been associated with type 2 diabetes [193] and is linked with
insulin action in adipocytes [194]. Serum Fetuin-A levels have been shown to correlate with metabolic
syndrome and its main features [191].
7.2.1. Fetuin-A and Diet
In the general population, circulating Fetuin-A was decreased by alcohol intake and milk/dairy
product intake, whereas meat and fish had no effect [195]. Resveratrol and curcumin intake may
decrease Fetuin-A release [196].
7.2.2. Fetuin-A and Exercise
Short-term exercise training has been shown to reduce Fetuin-A levels, contributing to
improvement in hepatic insulin sensitivity, especially in patients with NAFLD [197], although evidence
concerning other exercise regimens is still controversial [198].
7.2.3. Fetuin-A and Inflammation
Fetuin-A does not seem to be directly regulated by inflammation, and no correlation was observed
between hepatic inflammation and serum levels in patients with NAFLD [199].
7.2.4. Fetuin-A and NAFLD
Increased Fetuin-A has been reported in obese children and lean adults with NAFLD [199,200].
In patients with NAFLD, Fetuin-A levels were associated with the severity of steatosis, were influenced
by genetic risk factors for hepatic fat accumulation and also correlated with insulin resistance and
metabolic syndrome features [199]. Consistent with the above-mentioned lack of interplay between
Fetuin-A and inflammatory response, no correlation was observed between hepatic inflammation and
serum Fetuin-A levels in patients with NAFLD [189]. Fetuin-A could affect NAFLD/NASH because it
is implicated in the development of insulin resistance and accelerated atherogenesis associated with
fatty liver [199,201].
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7.2.5. Fetuin-A and Kidney
Fetuin-A is also an inhibitor of vascular calcification, is progressively reduced in patients with
renal failure and may modulate the progression of atherosclerosis in patients with chronic kidney
disease [202].
8. Conclusions
Recent years have brought a great deal of new insights into the complex and dynamic interplay
among the multiple effectors/mediators of fatty liver disease. Genomic, meta-genomic and metabolic
profiling technologies and other top-down systems biology approaches are well suited for studies
of metabolic syndrome and fatty liver disease. The appropriate analysis and interpretation of
the physiopathological signatures require a new system of approaches to study and stratify the
multifaceted clinical profiles of fatty liver and metabolic syndromes. Bio-statistical modeling will help
to identify and combine genomic and meta-genomic determinants of the metabolic pathways and
protein interaction networks. Similarly, the systems approach will help to stratify and re-define clinical
phenotypes assessing the multiple nature of disease susceptibility and progression. The integration of
metabolomic with genomic and meta-genomic markers will improve the understanding of metabolic
syndrome and fatty liver disease, and the combined molecular and clinic-pathologic stratification of
individuals with metabolic syndrome will allow redefining risks and prognoses, as well as identifying
new diagnostic criteria, new markers of disease progression and new endpoints of clinical trials for
specific groups of individuals with fatty liver.
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Abbreviations
AG acylated ghrelin
AMPK adenosine monophosphate-activated protein kinase
ANP atrial natriuretic peptide
BAT brown adipose tissue
BMI body mass index
CIMT carotid intima-media thickness




DKD diabetic kidney disease
DNL de novo lipogenesis
ELISA enzyme-linked immunosorbent assay
FC free cholesterol
FFA free fatty acid
FNDC5 fibronectin type III domain-containing protein 5
FoxO3a forkhead box O3a
FSGS focal segmental glomerular sclerosis
GLP-1 glucagon-like peptide 1
GLP-1R glucagon-like peptide 1 receptor
GNG gluconeogenesis
GOAT ghrelin-ghrelin O-acyltransferase
(Oct)-1 organic cation transporter
IR insulin resistance
IS insulin sensitive
JNK c-Jun terminal kinase
LDL low density lipoprotein
MRS magnetic resonance spectroscopy
MS metabolic syndrome
MUFA monounsaturated fatty acids
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
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NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
NGT normal glucose tolerance
NLRP3 nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3
NO nitric oxide
OGTT oral glucose tolerance test




SEPP1 selenoprotein P, plasma 1
SFA saturated fatty acids
T2D type 2 diabetes
TLR toll like receptors
TNF-α tumor necrosis factor-α
UCP1 uncoupling protein 1
VS visceral
VLDL very low density lipoprotein
WAT white adipose tissue
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